Summary Slide.png (104.3 kB)
Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
media
posted on 2021-02-05, 14:32 authored by Haleh Chehrehgosha, Masoud Reza Sohrabi, Faramarz Ismail-Beigi, Mojtaba Malek, Mohammad Reza babaei, Farhad Zamani, Hossein Ajdarkosh, Mahmood Khoonsari, Afshin Eshghi Fallah, Mohammad E. KhamsehArticle full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.
